Compare funds
Pick up to 10 funds. Compare funds from the same category for a fair reading.
Growth of ₹10,000
Basics
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| Category | Index Funds (Equity) | Index Funds (Equity) |
| Plan | Direct | Direct |
| Fund house | Tata | Axis |
| AUM | ₹210 Cr | ₹757 Cr |
| NAV | ₹15.9406 | ₹21.1061 |
| NAV date | 20 Nov 2026 | 20 Nov 2026 |
| History | — | 4.7 years |
| Expense ratio | 0.6% | 0.4% |
| Stars | Not rated | ★★★★★ |
| Growth Score | — | 57.80 |
AUM: AMFI's average assets under management for July - September 2026, in ₹ crore, for the whole fund (Direct and Regular, Growth and IDCW added up). The same source and period for every fund, so the figures compare.
Returns
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| 1 month | — | +4.51% |
| 3 months | — | +0.06% |
| 6 months | — | +12.76% |
| YTD | — | +15.40% |
| 1 year | — | +13.12% |
| 3 years (CAGR) | — | +15.26% |
| 5 years (CAGR) | — | — |
| 10 years (CAGR) | — | — |
| Since launch | — | +17.40% |
Risk
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| Volatility | — | 21.9% |
| Downside volatility | — | 13.4% |
| Sharpe | — | 0.40 |
| Sortino | — | 0.65 |
| Calmar | — | 0.61 |
| Return / risk | — | 0.70 |
| Deepest fall | — | −27.74% |
| Days to recover | — | 380 |
| Below its high | — | −1.48% |
Against benchmark
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| Alpha | — | — |
| Beta | — | — |
| R² | — | — |
| Up capture | — | — |
| Down capture | — | — |
| Tracking error | — | — |
| Information ratio | — | — |
| Treynor | — | — |
Consistency
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| Best 1-year | — | +80.07% |
| Middle 1-year | — | +13.12% |
| Worst 1-year | — | −17.32% |
| 1-year periods with a loss | — | 17.4% |
| Middle 3-year | — | +24.12% |
| Positive months | — | 58.3% |
| Best day | — | +4.79% |
| Worst day | — | −7.47% |
| Worst 5% day | — | −2.24% |
| Positive days | — | 55.5% |
| NAVs a year | — | 251 |
SIP of ₹10,000 a month
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| 5-year XIRR | — | — |
| 5-year value | — | — |
| 3-year XIRR | — | +11.96% |
| 1-year XIRR | — | +21.81% |
Holdings overlap i
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| Tata Nifty MidSmall Healthcare Index Fund Direct · filing Oct 2026 | — | 19% |
| Axis Nifty Smallcap 50 Index Fund Direct · filing Oct 2026 | 19% | — |
Share of money in the same stocks, by weight. Above 50% means much of one fund repeats the other.
Tata Nifty MidSmall Healthcare Index Fund and Axis Nifty Smallcap 50 Index Fund
Overlap
18.9%
smaller weight of each shared stock, added up
Stocks in common
10
of 30 and 50
Weight in common
24% · 19%
of each fund's money
Filings compared
Oct 2026 · Oct 2026
same month
| Common stock | Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | Counts toward overlap |
|---|---|---|---|
| Gland Pharma Limited | 3.72% | 2.98% | 2.98% |
| Sai Life Sciences Limited | 3.25% | 2.60% | 2.60% |
| Acutaas Chemicals Limited | 3.13% | 2.51% | 2.51% |
| Neuland Laboratories Limited | 2.56% | 2.05% | 2.05% |
| Wockhardt Limited | 2.37% | 1.89% | 1.89% |
| Dr. Lal Path Labs Limited | 2.24% | 1.79% | 1.79% |
| Piramal Pharma Limited | 2.24% | 1.79% | 1.79% |
| Onesource Specialty Pharma Limited | 1.85% | 1.48% | 1.48% |
| Natco Pharma Limited | 1.16% | 0.93% | 0.93% |
| Syngene International Limited | 1.15% | 0.92% | 0.92% |
| 10 stocks | 23.7% | 18.9% | 18.9% |
Only in Tata Nifty MidSmall Healthcare Index Fund (20)
| Laurus Labs Limited | 14.12% |
| Lupin Limited | 7.36% |
| Aurobindo Pharma Limited | 7.00% |
| Fortis Healthcare Limited | 6.03% |
| Glenmark Pharmaceuticals Limited | 5.22% |
| Alkem Laboratories Limited | 4.65% |
| Mankind Pharma Limited | 4.26% |
| IPCA Laboratories Limited | 4.04% |
| Biocon Limited | 3.70% |
| Krishna Institute Of Medical Sciences Limited | 2.82% |
| Aster DM Quality Care Limited | 2.74% |
| Ajanta Pharma Limited | 2.41% |
| Abbott India Limited | 2.01% |
| Granules India Limited | 1.87% |
| Narayana Hrudayalaya Limited | 1.79% |
| Global Health Limited | 1.70% |
| Glaxosmithkline Pharmaceuticals Limited | 1.56% |
| Anthem Biosciences Limited | 1.35% |
| Cohance Lifesciences Limited | 1.09% |
| Poly Medicure Limited | 0.83% |
Only in Axis Nifty Smallcap 50 Index Fund (40)
| Sona Blw Precision Forgings Limited | 4.83% |
| Karur Vysya Bank Limited | 4.06% |
| Ather Energy Limited | 4.02% |
| Navin Fluorine International Limited | 3.85% |
| Welspun Corp Limited | 3.70% |
| HFCL Limited | 2.86% |
| Delhivery Limited | 2.80% |
| Central Depository Services (India) Limited | 2.71% |
| RBL Bank Limited | 2.62% |
| City Union Bank Limited | 2.49% |
| Anand Rathi Wealth Limited | 2.48% |
| PNB Housing Finance Limited | 2.41% |
| Redington Limited | 2.34% |
| Angel One Limited | 2.22% |
| Poonawalla Fincorp Limited | 1.98% |
| TD Power Systems Limited | 1.96% |
| Great Eastern Shipping Co Limited | 1.91% |
| Manappuram Finance Limited | 1.91% |
| Computer Age Management Services Limited | 1.90% |
| Bandhan Bank Limited | 1.84% |
| Kirloskar Oil Engines Limited | 1.81% |
| MTAR Technologies Limited | 1.80% |
| Aegis Logistics Limited | 1.66% |
| Tata Elxsi Limited | 1.58% |
| Amber Enterprises India Limited | 1.55% |
and 15 smaller holdings (17.8% of the fund).
Method: from each fund's latest monthly portfolio filing, shares only (Indian and foreign equity; bonds, cash and derivatives are left out). Overlap adds up, for every stock both hold, the smaller of the two weights.
Sectors and company size
| Tata Nifty MidSmall Healthcare Index Fund | Axis Nifty Smallcap 50 Index Fund | |
|---|---|---|
| Large companies | — | — |
| Mid companies | 68.2% | 6.8% |
| Small companies | 32.0% | 91.2% |
| Top 10 holdings | 60.1% | 34.4% |
| Largest sector | Pharmaceuticals & Biotechnology 81% | Pharmaceuticals & Biotechnology 16% |